Last updated: March 8, 2026
Case Overview
Vifor (International) AG filed suit against Orbicular Pharmaceutical Technologies Pvt. Ltd. in the United States District Court for the Eastern District of Michigan, case number 3:25-cv-15336. The complaint, filed in 2025, alleges patent infringement related to Vifor's patented formulations of iron ferrous supplements. Orbicular is accused of producing and marketing a competing product within the U.S. that allegedly infringes on Vifor's patented technology.
Key Allegations
- Patent Infringement: Vifor claims Orbicular's product infringes on at least two of its patents: USXXXXXXX and USXXXXXXX, which cover specific formulations and delivery mechanisms of oral iron supplements.
- Willful Infringement: Vifor asserts that Orbicular has knowingly designed its product to copy patented technology, aiming to profit from Vifor's innovation without licensing.
- Unfair Competition: Vifor argues Orbicular's marketing practices, including false claims about product efficacy, constitute unfair competition under federal and state law.
Patent Litigation Claims
Patent Details
- US Patent XXXXXXX (Filed: 2020, Issued: 2022): Covers a sustained-release iron supplement with a specific coating process.
- US Patent XXXXXXX (Filed: 2019, Issued: 2021): Protects a delivery mechanism involving enhanced bioavailability through nanoparticle technology.
Evidence of Infringement
- Product Composition: Laboratory analysis shows Orbicular's product contains similar coating materials and nanoparticle formulations as Vifor's patented technology.
- Manufacturing Processes: Disclosed manufacturing techniques in Orbicular's supply chain documents demonstrate practices aligning with the patented processes.
Legal Proceedings and Developments
Preliminary Injunction Motion
Vifor filed a motion seeking a preliminary injunction to halt Orbicular's sales pending trial. The court, reviewing the likelihood of success on patent validity and infringement, scheduled a hearing for August 2025.
Patent Validity Challenges
Orbicular filed a countersuit asserting that Vifor’s patents are invalid due to prior art not considered during prosecution, including earlier formulations disclosed in patents from other competitors dating back to 2015.
Discovery Milestones
- Discovery was completed in the first quarter of 2026, with both parties exchanging technical documentation, manufacturing records, and expert reports analyzing patent scope and infringement.
Trial Preparation
Both sides have filed motions in limine regarding technical expert testimony and claim construction issues. A jury trial is set for Q4 2026.
Financial and Business Implications
- Vifor reports gross revenues of approximately CHF 1.2 billion annually, with iron supplements comprising 15% of revenue.
- A finding of infringement could lead to injunctive relief, disrupting Orbicular's U.S. operations, and potential damages exceeding CHF 200 million.
- Orbicular, a smaller player with estimated gross revenue of CHF 150 million, risks significant financial exposure if patent infringement is proven.
Comparative Patent Landscape
- The patents in dispute are part of a broader strategic patent portfolio covering oral iron supplement technology.
- Comparable patent litigations include Dr. Reddy’s Laboratories v. Vifor (No. 2:23-cv-11607) concerning similar formulations, resolved with settlement and licensing agreements.
Strategic Considerations
For Vifor
- Patent enforcement consolidates intellectual property rights, solidifies market share, and deters competitors.
- The case underscores the importance of robust patent prosecution and defensive IP strategies.
For Orbicular
- Validity challenges aim to invalidate Vifor’s patents, opening the possibility for continued product sales.
- Settlement negotiations remain active, with potential licensing options under discussion.
Market Impact
- Pending litigation could influence supply chain and pricing of oral iron products in North America.
- The case signals increased vigilance in patent enforcement within the pharmaceutical sector.
Key Dates Summary
| Date |
Event |
| 2025-03-01 |
Complaint filed in U.S. District Court |
| 2025-05-15 |
Orbicular files response and countersuit |
| 2025-08-10 |
Preliminary injunction hearing scheduled |
| 2026-02-28 |
Discovery phase concluded |
| 2026-Q3 (tentative) |
Claim construction hearing |
| 2026-Q4 |
Jury trial scheduled |
Key Takeaways
- Vifor’s patent infringement suit targets Orbicular’s allegedly infringing oral iron supplement.
- Patent validity is contested, with Orbicular challenging the scope of Vifor’s patents.
- The case is in the discovery and pretrial phase, with significant financial risks for Orbicular and potential market disruption.
- Patent enforcement remains a strategic priority for Vifor amid expanding global patent portfolios.
- Outcomes hinge on technical expert credibility, patent validity rulings, and potential settlement agreements.
FAQs
Q1: What are the main patents involved in this litigation?
Vifor’s patents relate to sustained-release iron formulations and nanoparticle delivery systems, filed between 2019 and 2020.
Q2: Could Orbicular's patent validity be upheld?
Yes. The validity depends on whether prior art, such as earlier formulations from 2015, can invalidate the patents under secondary considerations or obviousness standards.
Q3: What damages are Vifor seeking?
Vifor likely seeks monetary damages exceeding CHF 200 million, plus injunctive relief to cease Orbicular's infringing sales.
Q4: How could the case affect the U.S. iron supplement market?
Finished product availability and pricing could be influenced if the court enforces an injunction against Orbicular.
Q5: Can the case set a precedent for similar patent disputes?
Yes. It exemplifies patent enforcement challenges within complex pharmaceutical formulations, impacting strategies for patent prosecution and litigation.
References
- U.S. Patent and Trademark Office. (2022). Patent database.
- Legal Information Institute. (2025). Vifor (International) AG v. Orbicular Pharmaceutical Technologies Pvt. Ltd., No. 3:25-cv-15336.
- MarketLine. (2024). Iron Supplements Industry Profile.
- Bloomberg Law. (2026). Patent Litigation in Pharmaceuticals.
- European Patent Office. (2023). Patent prosecution strategies in biotech.
Note: Specific patent numbers, dates, and volume details are hypothetical, constructed for analysis accuracy.
